Nataly Martini provides a brief overview of selected causes of dizziness and vertigo, such as benign paroxysmal positional vertigo and vestibular migraine. Through case studies, she explains how these conditions may differ from serious clinical syndromes such as cervicogenic dizziness, highlighting the complexities, risk factors and management of these conditions
How to Manage: Codeine reclassification
How to Manage: Codeine reclassification
Concern about the increasing frequency of codeine misuse and abuse resulted in the Medicines Classification Committee recommending that all medicines containing codeine be reclassified as prescription medicines. This came into force on 5 November 2020. Clinical advisory pharmacists Linda Bryant and John Dunlop discuss reasons for this decision and provide tips for pharmacists to help patients with the transition
- Describe the reason for, and evidence supporting, the reclassification of codeine in combination medicines to prescription-only
- Identify the risks associated with codeine use, including those associated with metabolism
- Describe ways in which pharmacists can help patients who can no longer access codeine-containing products
This article has been republished, and access made free to readers, with the support of AFT Pharmaceuticals. The content is entirely independent and based on published studies and the author’s opinion.
This article was previously available on our ELearning platform. You can now download a PDF version of the article here:
This article has been endorsed by the Pharmaceutical Society of New Zealand and remains suitable for inclusion in a pharmacist’s continuing education records for continuing professional development purposes until 17/08/2022.